30
Participants
Start Date
November 4, 2013
Primary Completion Date
December 24, 2015
Study Completion Date
December 24, 2015
PF-03084014
Tablet, 10 mg, twice a day
PF-03084014
Tablet, 50 mg, twice a day
PF-03084014
Tablet, 100 mg, twice a day
Docetaxel
Solution for IV infusion 75 mg/m\^2, every 3 weeks
Docetaxel
Solution for IV infusion 100 mg/m\^2, every 3 weeks
Jules Bordet Institut, Brussels
Grand Hopital de Charleroi, Charleroi
Instituto Europeo di Oncologia, Milan
UNC Cancer Hospital Infusion Pharmacy, Chapel Hill
Hospital Universitario 12 de Octubre, Madrid
University of Alabama at Birmingham, Birmingham
University of Alabama at Birmingham, IDS Pharmacy, Birmingham
University of Alabama at Birmingham, Birmingham
Barbara Ann Karmanos Cancer Institute, Detroit
Karmanos Cancer Institute (KCI), Detroit
Stanford Cancer Institute, Stanford
Stanford Hospital & Clinics-DRUG SHIPMENT ADDRESS only, Stanford
Stanford Hospital & Clinics, Stanford
Stanford Women's Cancer Center, Stanford
UNC Hospitals, The University of North Carolina at Chapel Hill, Chapel Hill
Instituto Catalan de Oncologia de L'Hospitalet de Llobregat(ICO), Barcelona
Lead Sponsor
Pfizer
INDUSTRY